依达拉奉右莰醇联合丁苯酞氯化钠治疗急性脑梗死的系统评价  

Systematic Review on Edaravon Dexborneo Combined with Butylphthalide and Sodium Chloride in the Treatment of Acute Cerebral Infarction

作　　者：石岩硕 要凯青 曹格溪 赵建群[1] 庞国勋[1] 董占军[1] SHI Yanshuo;YAO Kaiqing;CAO Gexi;ZHAO Jianqun;PANG Guoxun;DONG Zhanjun(Dept.of Pharmacy,Heibei General Hospital,Shijiazhuang 050051,China;Gaocheng District Teaching Center of Shijiazhuang,Shijiazhuang 052165,China)

机构地区：[1]河北省人民医院药学部,石家庄050051 [2]石家庄市藁城区职教中心综合部,石家庄052165

出　　处：《中国医院用药评价与分析》2024年第5期598-601,605,共5页Evaluation and Analysis of Drug-use in Hospitals of China

基　　金：2021年度河北省医学科学研究课题计划(No.20211721)。

摘　　要：目的:系统评价依达拉奉右莰醇联合丁苯酞氯化钠治疗急性脑梗死的临床疗效和安全性。方法:计算机检索PubMed、中国生物医学文献数据库、中国知网、万方数据库、维普数据库等(检索时间为建库至2023年9月),收集依达拉奉右莰醇联合丁苯酞氯化钠(观察组)对比单纯使用丁苯酞氯化钠(对照组)治疗急性脑梗死临床疗效和安全性的随机对照试验(RCT),对符合纳入标准的临床研究进行资料提取和质量评价后,应用RevMan 5.3统计软件进行Meta分析。结果:最终纳入9项RCT,共995例患者,Meta分析结果显示,观察组患者总有效率(RR=1.21,95%CI=1.14~1.29,P<0.000 01)、痊愈率(RR=1.41,95%CI=1.08~1.83,P=0.01)和显效率(RR=1.35,95%CI=1.14~1.61,P=0.000 5)均高于对照组,美国国立卫生研究院脑卒中量表评分(MD=-3.08,95%CI=-4.23~-1.92,P<0.000 01)和无效率(RR=0.31,95%CI=0.21~0.46,P<0.000 01)显著低于对照组,差异均有统计学意义;两组患者改良Rankin量表评分(MD=-0.47,95%CI=-0.97~0.03,P=0.06)和不良反应发生率(RR=0.74,95%CI=0.49~1.12,P=0.15)的差异无统计学意义。结论:依达拉奉右莰醇联合丁苯酞氯化钠治疗急性脑梗死的临床疗效较单纯使用丁苯酞氯化钠更好,且安全性相当。OBJECTIVE:To systematically evaluate the efficacy and safety of edaravon dexborneo combined with butylphthalide and sodium chloride in the treatment of acute cerebral infarction.METHODS:PubMed,CBM,CNKI,Wanfang Data and VIP were retrieved to collect randomized controlled trial(RCT)of clinical efficacy and safety of edaravon dexborneo combined with butylphthalide and sodium chloride(observation group)compared with butylphthalein and sodium chloride alone(control group)in the treatment of acute cerebral infarction,the retrieval time was from database establishment to Sept.2023.After data extraction and quality evaluation,Meta-analysis was carried out by RevMan 5.3 statistical software.RESULTS:A total of 9 RCT including 995 patients were enrolled.Meta-analysis results showed that the total effective rate(RR=1.21,95%CI=1.14-1.29,P<0.00001),cure rate(RR=1.41,95%CI=1.08-1.83,P=0.01)and markedly effective rate(RR=1.35,95%CI=1.14-1.61,P=0.0005)in the observation group were higher than those in the control group,the National Institute of Health Stroke Scale score(MD=-3.08,95%CI=-4.23--1.92,P<0.00001)and inefficiency rate(RR=0.31,95%CI=0.21-0.46,P<0.00001)were significantly lower than those in the control group,with statistically significant differences.There were no significant differences in the modified Rankin scale score(MD=-0.47,95%CI=-0.97-0.03,P=0.06)and the incidence of adverse drug reactions(RR=0.74,95%CI=0.49-1.12,P=0.15)between two groups.CONCLUSIONS:The clinical efficacy of edaravon dexborneo combined with butylphthalein and sodium chloride in the treatment of acute cerebral infarction is better than that of butylphthalein and sodium chloride alone,and the safety is comparable.

关 键 词：依达拉奉右莰醇 丁苯酞氯化钠 急性脑梗死 META分析 

分 类 号：R973[医药卫生—药品]